| Trelegy Ellipta | A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | Phase 3 | Active not recruiting | 138 | Jan 26, 2027 |
| Adjuvanted RSVPreF3 vaccine | A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant | Phase 2 | Active not recruiting | 168 | Jan 12, 2027 |
| Shingrix | Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above | Phase 2 | Active not recruiting | 135 | Jan 2027 |
| MMB | Extended Access of Momelotinib in Adults With Myelofibrosis | Phase 2 | Active not recruiting | 237 | Dec 11, 2026 |
| Jemperli | A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer | Phase 2 | Active not recruiting | 154 | Nov 2, 2026 |
| dTpa vaccine | A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years | Phase 3 | Completed | 90 | Sep 4, 2026 |
| Jemperli | A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 | Phase 2 | Active not recruiting | 316 | Sep 1, 2026 |
| Digoxin | Digoxin Short Term Treatment Assessment Randomized Trial in AHF | Phase 3 | Completed | 500 | Aug 31, 2026 |
| Flu mRNA (Formulation B1) | A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above | Phase 2 | Completed | 971 | Aug 24, 2026 |
| iNTS-GMMA Dose C | A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants | Phase 2 | Completed | 180 | Aug 6, 2026 |
| felcorekibart | A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma | Phase 2 | Active not recruiting | 307 | Jul 17, 2026 |
| Jemperli | A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer | Phase 2 | Active not recruiting | 41 | Jul 15, 2026 |
| Jemperli | Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Terminated | 2 | Jul 13, 2026 |
| Zejula | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors | Phase 2 | Active not recruiting | 42 | Jun 30, 2026 |
| GSK4418959 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors | Phase 2 | Active not recruiting | 14 | Jun 22, 2026 |
| Belimumab Injection | Synergetic B-cell Immunomodulation in SLE - 2nd Study. | Phase 3 | Completed | 71 | Jun 22, 2026 |
| GSK4527226 | Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease | Phase 2 | Terminated | 367 | May 14, 2026 |
| Flu mRNA (Formulation A) | A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older | Phase 2 | Completed | 776 | May 11, 2026 |
| GSK4532990 | Phase 2b Study of GSK4532990 in Adults With NASH | Phase 2 | Completed | 284 | Jan 31, 2026 |
| Zanamivir | An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection | Phase 2 | Completed | 8 | Jan 14, 2026 |
| Flu Pandemic mRNA_Dose level 1 | A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults | Phase 2 | Completed | 991 | Jan 13, 2026 |
| camlipixant | A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough | Phase 3 | Completed | 957 | Dec 17, 2025 |
| rMenB+OMV NZ vaccine | A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old) | Phase 3 | Completed · results | 312 | Dec 15, 2025 |
| Bepirovirsen | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) | Phase 3 | Completed | 981 | Nov 11, 2025 |
| Bepirovirsen | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) | Phase 3 | Completed | 857 | Nov 3, 2025 |
| Mepolizumab | Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) | Phase 3 | Completed · results | 16 | Oct 28, 2025 |
| efimosfermin | A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension | Phase 2 | Completed | 231 | Oct 27, 2025 |
| altSonflex1-2-3 Dose A | A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants | Phase 2 | Completed · results | 200 | Oct 21, 2025 |
| Zejula | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | Phase 2 | Completed | 117 | Oct 15, 2025 |
| GSK3915393 | A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Terminated · results | 158 | Oct 1, 2025 |
| GSK4532990 | Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH | Phase 2 | Completed · results | 61 | Sep 23, 2025 |
| AFX3772 | A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants | Phase 2 | Completed · results | 388 | Sep 18, 2025 |
| Apretude | A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy | Phase 3 | Completed | 171 | Sep 16, 2025 |
| GSK3511294 (Depemokimab) | A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype | Phase 3 | Completed · results | 1,717 | Sep 14, 2025 |
| Salbutamol HFA-134a | A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma | Phase 3 | Completed · results | 471 | Sep 2, 2025 |
| GSK1070806 | Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. | Phase 2 | Terminated · results | 79 | Jul 29, 2025 |
| GSK1070806 | A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis | Phase 2 | Terminated · results | 161 | Jul 23, 2025 |
| Belantamab mafodotin | A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis | Phase 2 | Completed | 35 | Jul 17, 2025 |
| AltSonflex1-2-3 High Dose | A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants | Phase 2 | Completed · results | 551 | Jun 24, 2025 |
| 40 µg gE-gI | A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes | Phase 2 | Completed · results | 504 | Jun 12, 2025 |